Join us for a 1-hour webinar

The impact of minimal residual disease in acute leukemia is well established in patient outcome.

In this webinar, our guest speaker Evan Jensen, will review the evolution of clinical flow cytometry for the evaluation of minimal residual disease (MRD) in acute leukemia over the years. He will also describe the clinical relevance of MRD, current state-of-the-art methodology and the most important technical aspects to perform a good flow cytometry measurement.

Agenda:

• The beginnings and historical perspective of acute leukemia MRD evaluation
• Most important aspects to perform MRD by flow cytometry
• Next Generation Flow in MRD for acute B lymphoblastic leukemia
• Analysis of practical cases
• Q&A session

Evan Jensen is currently the co-head of the Cytometry service at the National Children’s Hospital, which is a national reference center, where he carries out the immunophenotyping of hematological and immunological neoplasms in children and adults. He was trained in the Cytometry Service of the University of Salamanca and the Portuguese Institute of Oncology (IPO). He is professor in the specialty of Hematology at the University of Costa Rica. Evan is also the founder and director of the Jensen Private Laboratory and a certified cytometrist by the American Society of Clinical Pathology (ASCP).

7 PM GMT+2 (Madrid, Spain)
7 PM GMT+2 (Amsterdam, Netherlands)
1 AM GMT+8 (Beijing, China)
3 AM GMT+10 (Sydney, Australia)
2 PM GMT-3 (Rio de Janeiro, Brasil)
1 PM GMT-4 (New York, NY, USA)
10 AM GMT-7 (Los Angeles, CA, USA)
5 PM GMT